During the past decade, Cancercare conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 8 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cancercare" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Pfizer" with 3 trials sponsored, "BioVex Limited" with 1 trials sponsored, "Puma Biotechnology, Inc." with 1 trials sponsored and "mAbxience Research S.L." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cancercare" #1 collaborator was "Actoverco" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Innogene Kalbiotech Pte. Ltd" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Cancercare" are "Breast Cancer" (2 trials), "Castration-Resistant Prostate Cancer" (1 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "Esophageal Squamous Cell Carcinoma" (1 trials) and "Kidney Neoplasms" (1 trials). Many other conditions were trialed in "Cancercare" in a lesser frequency.

Most popular intervention types in "Cancercare" are "Drug" (10 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Paclitaxel" (3 trials), "Placebo" (3 trials), "Active Comparator (erlotinib)" (1 trials) and "Atezolizumab Matching Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cancercare" are 10 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Cancercare". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Cancercare, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Cancercare, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".